MDEV - ETF AI Analysis
Top Page
First Trust Indxx Medical Devices ETF (MDEV)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance in Key Holdings
Several of the largest positions, including West Pharmaceutical Services, LivaNova, Baxter, Revvity, Dexcom, WuXi AppTec, and Straumann, have shown strong gains this year, helping support the fund despite overall weakness.
Global Diversification
The ETF invests mainly in U.S. companies but also has meaningful exposure to markets like Japan, Switzerland, Hong Kong, Germany, and France, which helps spread country-specific risk.
Focused Exposure to Health Care Devices
With most assets in the health care sector and specifically medical devices, the fund offers targeted access to a specialized area that can benefit from long-term trends in health care demand and innovation.
Negative Factors
Weak Overall Year-to-Date Performance
Despite some strong individual stocks, the ETF’s overall performance this year has been negative, which may concern investors looking for steady growth.
High Expense Ratio
The fund’s relatively high expense ratio means more of investors’ returns are eaten up by fees compared with lower-cost ETFs.
Sector Concentration Risk
Because the ETF is heavily concentrated in health care and medical devices, it is more vulnerable if this single sector faces regulatory changes, reimbursement pressure, or industry-specific downturns.
MDEV vs. SPDR S&P 500 ETF (SPY)
AUM3.20M
RegionGlobal
Expense Ratio0.70%
Beta0.72
IssuerFirst Trust
Inception DateJun 22, 2021
Dividend Yield0.1%
Asset ClassEquity
Index TrackedIndxx Global Medical Equipment Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,168
30 Day Avg. Volume3,222
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
23.75Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MDEV Summary
The First Trust Indxx Medical Devices ETF (MDEV) is a fund that follows the Indxx Global Medical Equipment Index and focuses on companies that make medical devices used in hospitals, clinics, and labs. It holds a mix of health care equipment makers such as Baxter International and Dexcom, which produce products like infusion pumps and blood sugar monitors. Someone might invest in MDEV to seek growth from an aging population and rising demand for medical technology, while also getting global diversification within health care. A key risk is that it is heavily concentrated in medical device and health care stocks, so it can rise or fall with that specific sector.
How much will it cost me?The First Trust Indxx Medical Devices ETF (MDEV) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized niche in the health care sector, requiring more research and management effort. While it costs more, it provides targeted exposure to innovative medical device companies.
What would affect this ETF?The First Trust Indxx Medical Devices ETF (MDEV) could benefit from positive trends such as aging populations, increasing global health care spending, and ongoing advancements in medical technology, which drive demand for innovative medical devices. However, potential risks include regulatory changes, rising interest rates that could impact borrowing costs for companies in the sector, and global economic slowdowns that may reduce health care budgets. As a globally focused ETF with exposure to leading medical device companies like Sartorius Stedim Biotech and HOYA, its performance will also depend on international market conditions and currency fluctuations.
MDEV Top 10 Holdings
MDEV is a pure play on global medical devices, with names like Dexcom and West Pharmaceutical Services doing much of the heavy lifting as their momentum stays firmly in the “rising” camp. Agilent and Revvity are also contributing, though their rich valuations keep enthusiasm a bit in check. On the other side, Baxter and Bio-Rad feel more like dead weight, with ongoing financial and technical challenges that have been lagging the pack. With holdings spread across the U.S., Europe, and Asia, the fund is globally diversified but tightly focused on health care equipment.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Baxter International | 2.80% | $88.88K | $13.35B | 5.77% | 45 Neutral | |
| WuXi AppTec Co., Ltd. Class H | 2.75% | $87.17K | HK$535.38B | 68.22% | 69 Neutral | |
| ― | 2.71% | $85.97K | ― | ― | ― | |
| Revvity | 2.70% | $85.55K | $14.53B | 50.30% | 67 Neutral | |
| Sysmex | 2.68% | $85.20K | ¥1.21T | -0.40% | 61 Neutral | |
| Bio-Rad Laboratories | 2.57% | $81.47K | $10.37B | 30.69% | 54 Neutral | |
| Dexcom | 2.55% | $80.96K | $33.17B | 9.18% | 79 Outperform | |
| Olympus | 2.51% | $79.67K | $14.52B | 3.53% | 68 Neutral | |
| West Pharmaceutical Services | 2.45% | $77.85K | $23.93B | 35.59% | 68 Neutral | |
| Merit Medical Systems | 2.44% | $77.41K | $5.35B | -3.62% | 68 Neutral |
MDEV Technical Analysis
Neutral
―
Price Trends
20.44
Positive
19.59
Positive
20.03
Positive
Market Momentum
0.21
Positive
48.42
Neutral
21.78
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MDEV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 21.38, equal to the 50-day MA of 20.44, and equal to the 200-day MA of 20.03, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 48.42 is Neutral, neither overbought nor oversold. The STOCH value of 21.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MDEV.
MDEV Peer Comparison
Comparison Results
Performance Comparison
MDEV
First Trust Indxx Medical Devices ETF
20.96
0.18
0.87%
HTEC
ROBO Global Healthcare Technology and Innovation ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents